2-异丙基-2H-吡唑-3-甲醛 | 100305-93-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-异丙基-2H-吡唑-3-甲醛
• 中文别名: 1-异丙基吡唑-5-甲醛
• 英文名称: 1-isopropyl-1H-pyrazole-5-carbaldehyde
• 英文别名: 2-propan-2-ylpyrazole-3-carbaldehyde
• CAS: 100305-93-9
• 化学式: C₇H₁₀N₂O
• mdl: MFCD03130042
• 分子量: 138.169
• InChiKey: JGQABCBGCJORGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  温度控制在2至8℃范围内，并置于惰性气体环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Isopropylpyrazole-3-carbaldehyde
Synonyms: 5-Formyl-1-isopropylpyrazole

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Isopropylpyrazole-3-carbaldehyde
CAS number: 100305-93-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H10N2O
Molecular weight: 138.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-异丙基-2H-吡唑-3-甲醛 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 17.0h， 以1.7 g的产率得到[1-(propan-2-yl)-1H-pyrazol-5-yl]methanol
  参考文献：
  名称：

  发现S64315，一种有效且选择性的Mcl-1抑制剂

  摘要：

  髓样细胞白血病1（Mcl-1）已成为癌症治疗的诱人靶标。它是Bcl-2蛋白质家族的抗凋亡成员，其在人类癌症中的上调与较高的肿瘤等级，较差的生存率和对化学疗法的抗性有关。在这里，我们报告了我们的临床候选药物S64315的发现，S64315是Mcl-1的选择性小分子抑制剂。从片段衍生的先导化合物开始，我们进行了结构指导的优化，从而导致靶标亲和力和细胞效价显着提高（3 log）。沿联芳基轴旋转受阻的存在赋予了化合物对抗Bcl-2家族其他成员的高选择性。在优化期间，我们还建立了Mcl-1抑制的预测性PD标志物，并在Mcl-1依赖性癌症模型中实现了有效的体外细胞杀伤和肿瘤消退。临床前候选药物具有类似药物的特性，使其得以开发并进入临床试验。

  DOI：

  10.1021/acs.jmedchem.0c01234
• 作为产物：
  描述：

  N,N-二甲基甲酰胺 、 1-异丙基吡唑 在 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 2-异丙基-2H-吡唑-3-甲醛
  参考文献：
  名称：

  发现S64315，一种有效且选择性的Mcl-1抑制剂

  摘要：

  髓样细胞白血病1（Mcl-1）已成为癌症治疗的诱人靶标。它是Bcl-2蛋白质家族的抗凋亡成员，其在人类癌症中的上调与较高的肿瘤等级，较差的生存率和对化学疗法的抗性有关。在这里，我们报告了我们的临床候选药物S64315的发现，S64315是Mcl-1的选择性小分子抑制剂。从片段衍生的先导化合物开始，我们进行了结构指导的优化，从而导致靶标亲和力和细胞效价显着提高（3 log）。沿联芳基轴旋转受阻的存在赋予了化合物对抗Bcl-2家族其他成员的高选择性。在优化期间，我们还建立了Mcl-1抑制的预测性PD标志物，并在Mcl-1依赖性癌症模型中实现了有效的体外细胞杀伤和肿瘤消退。临床前候选药物具有类似药物的特性，使其得以开发并进入临床试验。

  DOI：

  10.1021/acs.jmedchem.0c01234

文献信息

• Substituted Pyrrolidines and Methods of Use
  申请人：AbbVie S.à.r.l.

  公开号：US20180099931A1

  公开（公告）日：2018-04-12

  The invention discloses compounds of Formula (I) wherein R 1 , R 2 , R 2A , R 3 , R 3A , R 4 , R 4A , and R 5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

  该发明公开了式（I）的化合物 其中R 1 ，R 2 ，R 2A ，R 3 ，R 3A ，R 4 ，R 4A 和R 5 如本文所定义。本发明涉及化合物及其在囊性纤维化治疗中的应用，其生产方法，包含相同化合物的药物组合物，以及通过给予该发明的化合物来治疗囊性纤维化的方法。
• Catalyst-free addition of secondary phosphine chalcogenides to pyrazolecarbaldehydes
  作者：Svetlana F. Malysheva、Vladimir A. Kuimov、Natalia A. Belogorlova、Nina K. Gusarova、Ilya V. Taydakov、Alexander I. Albanov、Igor L. Eremenko、Boris A. Trofimov

  DOI：10.1016/j.mencom.2019.11.027

  日期：2019.11

  (Chalcogenophosphoryl)( hydroxyl)methyl-substituted pyrazoles were obtained by catalyst-free reaction between 4- and 5-pyrazolecarbaldehydes and secondary phosphine chalcogenides R2P(X)H [R = Ph, (CH2)(2)Ph, X = O, S, Se] at 23-50 degrees C in toluene.

  通过无催化剂条件下的反应，以4-和5-嘧啶酮醛为底物，与次磷酸烷基化物R2P(X)H [R = Ph, (CH2)2Ph, X = O, S, Se]在23-50°C的条件下，于甲苯中合成了（含氧硫磷酰基）（羟基）甲基取代的嘧啶。
• Indazolones as modulators of TNF signaling
  申请人：AbbVie Inc.

  公开号：US10273238B2

  公开（公告）日：2019-04-30

  The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.

  本公开提供了式 (I) 的化合物 药学上可接受的盐、原药、生物活性代谢物、立体异构体和异构体，其中变量在本文中定义。本公开的化合物可用于治疗免疫学和肿瘤学疾病。
• Substituted pyrrolidines and methods of use
  申请人：AbbVie S.à.r.l.

  公开号：US10399940B2

  公开（公告）日：2019-09-03

  The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

  本发明公开了式 (I) 的化合物 其中 R1、R2、R2A、R3、R3A、R4 和 R5 如本文所定义。本发明涉及治疗囊性纤维化的化合物及其用途、生产方法、包含本发明化合物的药物组合物以及通过施用本发明化合物治疗囊性纤维化的方法。
• SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS
  申请人：AbbVie Overseas S.à r.l.

  公开号：EP3523277B1

  公开（公告）日：2021-06-30